Skip to main content
Top

Open Access 13-05-2024 | Glucose Monitoring and Insulin Delivery Devices | Review

The role of automated insulin delivery technology in diabetes

Authors: Charlotte K. Boughton, Roman Hovorka

Published in: Diabetologia

Login to get access

Abstract

The role of automated insulin delivery systems in diabetes is expanding. Hybrid closed-loop systems are being used in routine clinical practice for treating people with type 1 diabetes. Encouragingly, real-world data reflects the performance and usability observed in clinical trials. We review the commercially available hybrid closed-loop systems, their distinctive features and the associated real-world data. We also consider emerging indications for closed-loop systems, including the treatment of type 2 diabetes where variability of day-to-day insulin requirements is high, and other challenging applications for this technology. We discuss issues around access and implementation of closed-loop technology, and consider the limitations of present closed-loop systems, as well as innovative approaches that are being evaluated to improve their performance.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
33.
go back to reference Choudhary P, Arrieta A, van den Heuvel T, Castaneda J, Smaniotto V, Cohen O (2024) Celebrating the data from 100,000 real-world users of the MiniMed™ 780G system in Europe, Middle East, and Africa collected over 3 years: from data to clinical evidence. Diabetes Technol Ther 26(S3):32–7. https://doi.org/10.1089/dia.2023.0433CrossRefPubMed Choudhary P, Arrieta A, van den Heuvel T, Castaneda J, Smaniotto V, Cohen O (2024) Celebrating the data from 100,000 real-world users of the MiniMed™ 780G system in Europe, Middle East, and Africa collected over 3 years: from data to clinical evidence. Diabetes Technol Ther 26(S3):32–7. https://​doi.​org/​10.​1089/​dia.​2023.​0433CrossRefPubMed
54.
go back to reference Boughton CK, Hartnell S, Thabit H et al (2021) Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study. Diabetes Obes Metab 23(6):1389–96. https://doi.org/10.1111/dom.14355CrossRefPubMed Boughton CK, Hartnell S, Thabit H et al (2021) Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study. Diabetes Obes Metab 23(6):1389–96. https://​doi.​org/​10.​1111/​dom.​14355CrossRefPubMed
56.
go back to reference Lee MH, Paldus B, Vogrin S et al (2021) Fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system in adults with type 1 diabetes: a randomized, open-label, crossover trial. Diabetes Care 44(10):2371–78. https://doi.org/10.2337/dc21-0814CrossRef Lee MH, Paldus B, Vogrin S et al (2021) Fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system in adults with type 1 diabetes: a randomized, open-label, crossover trial. Diabetes Care 44(10):2371–78. https://​doi.​org/​10.​2337/​dc21-0814CrossRef
58.
go back to reference Boughton CK, Hartnell S, Lakshman R et al (2023) Fully closed-loop glucose control compared with insulin pump therapy with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control: a single-center, randomized, crossover study. Diabetes Care 46(11):1916–22. https://doi.org/10.2337/dc23-0728CrossRefPubMed Boughton CK, Hartnell S, Lakshman R et al (2023) Fully closed-loop glucose control compared with insulin pump therapy with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control: a single-center, randomized, crossover study. Diabetes Care 46(11):1916–22. https://​doi.​org/​10.​2337/​dc23-0728CrossRefPubMed
61.
go back to reference Haidar A, Yale JF, Lovblom LE et al (2021) Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial. Diabetes Obes Metab 23(6):1272–81. https://doi.org/10.1111/dom.14335CrossRefPubMed Haidar A, Yale JF, Lovblom LE et al (2021) Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial. Diabetes Obes Metab 23(6):1272–81. https://​doi.​org/​10.​1111/​dom.​14335CrossRefPubMed
Metadata
Title
The role of automated insulin delivery technology in diabetes
Authors
Charlotte K. Boughton
Roman Hovorka
Publication date
13-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-024-06165-w
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare